April 1, 2024Lara D. VeekenOpen Access

OA16 Clinical and biochemical improvement following daratumumab therapy for anti-MDA5 antibody positive dermatomyositis with rapidly progressive interstitial lung disease: a case report

View Full Paper

Ask AI

Bookmark

Anti-MDA5 antibody seroconverted to negative and ferritin normalised following daratumumab therapy in a refractory dermatomyositis patient with interstitial lung disease.
Case report describes four intravenous daratumumab doses administered after six months of failure with plasmapheresis, rituximab, methylprednisolone, and tofacitinib therapy.
Highlights daratumumab as a potential salvage therapy depleting CD38-positive long-lived plasma cells in refractory dermatomyositis, though single-case findings warrant wider study.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Case report demonstrates clinical and biochemical improvement following daratumumab in refractory anti-MDA5 dermatomyositis, highlighting anti-CD38 therapy as a potential salvage option.

Cite This Study

Koh et al. (2024) studied this question.

synapsesocial.com/papers/68e71600b6db64358768e744 https://doi.org/10.1093/rheumatology/keae163.016

View Full Paper

Ask AI

Bookmark

Implication

Case report demonstrates clinical and biochemical improvement following daratumumab in refractory anti-MDA5 dermatomyositis, highlighting anti-CD38 therapy as a potential salvage option.

OA16 Clinical and biochemical improvement following daratumumab therapy for anti-MDA5 antibody positive dermatomyositis with rapidly progressive interstitial lung disease: a case report

Key Points

Discussion

Implication

Cite This Study

OA16 Clinical and biochemical improvement following daratumumab therapy for anti-MDA5 antibody positive dermatomyositis with rapidly progressive interstitial lung disease: a case report

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider